General Meeting Presentation
Released
Released
Announcement PDF
0
General
Meeting
ASX:RCE | FSE:R9Q
September 2026
Disclaimer
DISCLAIMER
This presentation has been prepared by Recce Pharmaceuticals Ltd (the “Company”). It does
not purport to contain all the information that a prospective investor may require in connection
with any
potential investment in the Company. You should not treat the contents of this presentation,
or any information provided in connection with it, as financial advice, financial product advice
or advice relating to legal, taxation or investment matters.
No representation or warranty (whether express or implied) is made by the Company or any
of its officers, advisers, agents or employees as to the accuracy, completeness or
reasonableness of the information, statements, opinions or matters (express or implied)
arising out of, contained in or derived from this presentation or provided in connection with it,
or any omission from this presentation, nor as to the attainability of any estimates, forecasts
or projections set out in this presentation.
This presentation is provided expressly on the basis that you will carry out your own
independent inquiries into the matters contained in the presentation and make your own
independent decisions about the affairs, financial position or prospects of the Company. The
Company reserves the right to update, amend or supplement the information at any time in its
absolute discretion (without incurring any obligation to do so).
Neither the Company, nor its related bodies corporate, officers, their advisers, agents and
employees accept any responsibility or liability to you or to any other person or entity arising
out of this presentation including pursuant to the general law (whether for negligence, under
statute or otherwise), or under the Australian Securities and Investments Commission Act
2001, Corporations Act 2001, Competition and Consumer Act 2010 or any corresponding
provision of any Australian state or territory legislation (or the law of any similar legislation in
any other jurisdiction), or similar provision under any applicable law. Any such responsibility or
liability is, to the maximum extent permitted by law, expressly disclaimed and excluded.
Nothing in this material should be construed as either an offer to sell or a solicitation of an
offer to buy or sell securities. It does not include all available information and should not be
used in isolation as a basis to invest in the Company.
1
FUTURE MATTERS
This presentation contains reference to certain intentions, expectations, future plans, strategy and prospects of
the Company.
Those intentions, expectations, future plans, strategy and prospects may or may not be achieved. They are
based on certain assumptions, which may not be met or on which views may differ and may be affected by
known and unknown risks. The performance and operations of the Company may be influenced by a number of
factors, many of which are outside the control of the Company. No representation or warranty, express or
implied, is made by the Company, or any of its directors, officers, employees, advisers or agents that any
intentions, expectations or plans will be achieved either totally or partially or that any particular rate of return will
be achieved.
Given the risks and uncertainties that may cause the Company’s actual future results, performance or
achievements to be materially different from those expected, planned or intended, recipients should not place
undue reliance on these intentions, expectations, future plans, strategy and prospects. The Company does not
warrant or represent that the actual results, performance or achievements will be as expected, planned or
intended.
US DISCLOSURE
This document does not constitute any part of any offer to sell, or the solicitation of an offer to buy, any
securities in the United States or to, or for the account or benefit of any “US person” as defined in Regulation S
under the US Securities Act of 1993 (“Securities Act”). The Company’s shares have not been, and will not be,
registered under the Securities Act or the securities laws of any state or other jurisdiction of the United States,
and may not be offered or sold in the United States or to any US person without being so registered or
pursuant to an exemption from registration including an exemption for qualified institutional buyers.
Recce Pharmaceuticals – Company Overview
RECCE® 327 granted Qualified Infectious Disease Product (QIDP)
Designation by U.S. Food and Drug Administration giving 5 years
market exclusivity plus fast-track approval.
RECCE® 327 added to World Health Organization’s List
of Antibacterial Products in Clinical Development.
2
Recce Pharmaceuticals is a leading, Australian anti-infective company approaching near term commercialisation milestones
Products address the global healthcare crisis of antibiotic resistance: working faster
than traditional antibiotics and against multidrug resistant bacteria
Patient dosing has commenced for Phase 3 clinical trials in Australia and Indonesia
of lead asset RECCE® 327 Gel for the treatment of Diabetic Foot Infections – interim data
readout expected Q3 CY2026 and commercialisation in 2027
Recce has signed a non-binding term sheet with a leading Middle Eastern
pharmaceutical company for a 10-Year exclusive multi-country licensing agreement
Multiple clinical indications and formulations addressing unmet medical needs
Agreements with US Defense Burn Research Program and US Army Medical
Research Institute of Infectious Diseases further support Recce's product potential
Board and Management Structure
3
Dr John Prendergast – Chairman
BSc (Hons), MSc (UNSW), PhD (UNSW), CSS (HU)
US-based, current Chairman and Co-founder of Palatin Technologies, Inc.
(NYSE: PTN) and Lead Director of Nighthawk Biosciences (NYSE: HHWK). With
extensive experience in the international commercialisation of pharmaceutical
technologies, Dr Prendergast has been responsible for the approval of three
new drug applications and played a pivotal role in the successful sale of
Vylessi® to Cosette Pharmaceuticals
James Graham – Managing Director & Chief Executive Officer
BCom (Entrepreneurship), GAICD
Mr Graham is the Chief Executive Officer of Recce Pharmaceuticals. He brings
extensive experience in marketing, business development, and the
commercialisation of early-stage technologies with global potential. With a
proven track record of growing globally focused companies, Mr Graham has
applied his expertise to Recce, including serving on its Board of Directors. He
has participated in nearly every capital raise to date, demonstrating a strong
commitment to expanding Recce’s commercial opportunities and clinical
programs.
Dr Alan Dunton – Chief Medical Advisor & Non-Executive Director
BSc (BioChem) Hons, M.D. (NYU)
US based, Director of Palatin Technologies. Over three decades of senior
pharmaceutical experience incl. President and MD of Janssen Research
Foundation (Johnson & Johnson). Dr Dunton has advanced a number of
blockbuster antibiotics through regulatory review and commercialisation at
Fortune 500 companies including Roche. Dr Dunton has been responsible for
the approval of approximately 20 New Drug Applications. Dr. Dunton played
a key role in the sale of Vylessi® to Cosette Pharmaceuticals for USD $159
million in contingent, sales-based milestones, continuing his track record of
fostering advancements in drug development and successful commercialisation
efforts.
Michele Dilizia – Executive Director & Chief Scientific Officer
BSc (Med Sci), Grad Dip Bus (Mkting), BA (Journ), GAICD, MASM
Co-inventor and qualified medical scientist with a specialisation in medical
microbiology and regulatory affairs. Ms Dilizia successfully co-led the
research and development of Recce’s suite of anti- infective
compounds, resulting in a portfolio of granted patents across the globe,
including a Qualified Infectious Disease Product designation with the U.S.
FDA.
Dr Justin Ward – Executive Director & Principal Quality Chemist
BSc (Chem), PhD (Chem), M Pharm, MRACI, CChem
A quality control expert who has worked with leading pharmaceutical
companies. He previously held a technical role with Pfizer, involving providing
data for the regulatory submissions to the FDA and TGA. Dr Ward is bringing
Recce’s research and development and manufacturing up to US FDA
requirements.
Alistair McKeough – Non-Executive Director
Mr McKeough is an experienced executive and solicitor. Before being
appointed as a non-executive director in 2022, Alistair served as Recce’s
company secretary and he has been involved with the company since 2017.
Alistair has extensive experience in a variety of private and listed corporations
across many sectors, including professional services, technology, financial
services, charities, health, biotech, childcare and education. Recent roles
include Managing Director of a legal practice specialising in equity capital
markets and advice to listed companies and as part of the senior leadership
team at share registry, Automic Group.
Elusys Therapeutics
Registrational Phase 3 Clinical Trial - Indonesia
4
Study Title: Phase 3, Double-blind, Placebo-Controlled Study of R327 Topical Gel for the Treatment of Diabetic Foot Ulcer Infections
Multi-centre, 5 activated
sites across Indonesia.
Over 20.9 million adults in
Indonesia are living with
diabetes – more than 1 in
every 10 adults.
Up to 310 participants will
be enrolled who present with
a mild diabetic foot infection.
Interim data analysis to be
conducted after 155
participants.
Primary Endpoint: Assess the
clinical response of the DFI
according to the Lipsky Scale.
Secondary Endpoints: DFI total
wound score and safety of R327G.
Population
Locations Endpoints
Intervention
Participants to receive either R327
topical gel or placebo topical gel.
Phase 3 DFI Clinical Trial Expands in Australia
5
Study Design
• 208 patients total with interim analysis to be conducted
after 104 participants
• Patient dosing continues under existing protocol
• Wound imaging added, calibrated digital photography for
standardised, objective assessment
Participants
• Phase 3 global regulatory strategy targeting approvals
across Australia (TGA), the US (FDA), MENA and ASEAN
• R327G to be positioned as first standard of care
treatment for DFIs - no specific standard of care exists for
DFI
Strategic Significance
Randomised between R327G and one of four physician-selected comparator antibiotics
HREC approves protocol amendment adding randomised, active-controlled, non-inferiority + superiority component
Randomised, active-controlled, non-inferiority design and includes a superiority analysis
Phase 3 DFI Clinical Trial Expands in Australia & Indonesia
6
HREC approves protocol amendment adding randomised, active-controlled, non-inferiority component
Ulcer
Severy
Criteria
Below ankle
Mild only
Single ulcer
Below knee
Mild to moderate
Per ulcer basis
Was
33%
Moderate
DFI
47%
Mild DFI
~80%
Total Mild + Moderate
HREC approval significantly expands DFI
patient pool from Mild to Mild + Moderate
Now
Large Addressable Market
7
The global diabetic foot infection (DFI) market represents a substantial burden on global healthcare systems
US$5.8B
Est. global DFI
treatment
market1
Source: (1) Grand View Research, Diabetic Foot Ulcer Treatment Market Size, 2025 (2) Grand View Research, Anti-Infective Agents Market Size, 2023 (3) Diabetes Atlas, International Diabetes Federation (IDF) and Prof EM Yunir, Faculty of
Medicines, University of Indonesia. (4) https://diabetesatlas.org/data-by-location/region/middle-east-and-north-africa/ (5) https://idf.org/about-diabetes/diabetes-facts-figures/ (6) The current burden of diabetic foot disease – PMC (7)
https://doi.org/10.1016/j.heliyon.2024.e41263 (8) https://westernsydneydiabetes.com.au/framework-for-change/enhanced-management/save-a-leg/
INDONESIA MENA GLOBAL
>20 million
adults in Indonesia with
diabetes3
>84 million
adults in MENA region
with diabetes4
>589 million
adults globally with
diabetes5
Est. global market
opportunities in the
anti-infectives
market2
• For adults with diabetes, approximately one in three adults
will develop a diabetic foot ulcer in their lifetime6
• In Indonesia, DFIs are severe in 67.1% of hospitalised cases
and result in amputation in 46.9% of patients7
• Diabetes is responsible for 60% of all amputations in
Australia, and it has one of the worst diabetes-related lower
limb amputation rates in the developed world, with nearly 20
per 100,000 people with diabetes losing a limb compared to an
average of 12 per 100,000 elsewhere.8
US$135.4B
recce.com.au
Program Pipeline* driven by 1st approval in Diabetic Foot Infections
2026 2027 2028 2029 2030
R327 Topical
R327 Topical
R327 I.V. Program
R327 Inhaled – Lung Infections
Civil & Dept of War Programs
Phase 3 Interim Data Readout - 155
patients
Hospital Acquired Pneumonia (HAP)
Ventilator Assisted Pneumonia (VAP)
DFI/ABSSSI AUSTRALIA/USA
Diabetic Foot Ulcer Infection GEL
INDONESIA/ASEAN
Burn Wound Infections USA
Mechanism of Action (MoA)
Peer Reviewed Publication
MoA paper
published
Phase I/II Trials of R327
Nebuliser
Preclinical Trials of R327
Nebuliser
Registrational Trials of
R327 Nebuliser
R327G
Registered
in Indonesia
Potential Phase II Trials of R327 IV
Preclinical Trials of R327G with
Department of War (DoW)
Additional Registrational Clinical
Trials and Data for AUS/US Approval
Indo trial data
used for global
registration strategy
R327G
Registered
in ASEAN
R327G
Registered in
Australia/US
File NDA
Phase I Complete,
safe and well tolerated
*The information and forecasts presented reflect management’s current expectations as at the date of this presentation. These statements involve assumptions, including the availability of appropriate
funding, and are subject to known and unknown risks and uncertainties. Actual outcomes may differ from those expressed or implied and the Company reserves the right to revise its plans, projections,
and strategic priorities as circumstances change.
Registrational Trials of R327G
For Burn Wounds
recce.com.au
Thank you
Share your feedback
Discover